Nomura Holdings’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-36,400
Closed -$1.21M 1263
2019
Q1
$1.21M Buy
+36,400
New +$1.11M 0.01% 785
2016
Q2
Sell
-7,900
Closed -$296K 1485
2016
Q1
$296K Buy
+7,900
New +$298K ﹤0.01% 1055
2015
Q1
Sell
-9,745
Closed -$332K 2101
2014
Q4
$332K Buy
9,745
+8,005
+460% +$284K ﹤0.01% 1858
2014
Q3
$66K Sell
1,740
-60,192
-97% -$2.25M ﹤0.01% 2596
2014
Q2
$2.38M Buy
61,932
+59,460
+2,405% +$2.21M ﹤0.01% 1037
2014
Q1
$84K Sell
2,472
-157,744
-98% -$4.89M ﹤0.01% 2537
2013
Q4
$3.36M Buy
160,216
+83,185
+108% +$2.1M 0.02% 501
2013
Q3
$1.83M Buy
+77,031
New +$2.19M 0.01% 866

Other funds holding MYGN

Nomura Holdings's MYGN Position: Q2 2019 in Review

Nomura Holdings sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 36,400 shares — an estimated $1.21M sold.

Nomura Holdings first reported a position in MYGN in Q3 2013 and held it in 8 quarters. The position peaked at $3.36M in Q4 2013. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • Nomura Holdings reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • Nomura Holdings sold 36,400 Myriad Genetics shares in Q2 2019, an estimated $1.21M.
  • Nomura Holdings first reported a position in Myriad Genetics in Q3 2013 and held it in 8 quarters.
  • Nomura Holdings's Myriad Genetics position peaked at $3.36M in Q4 2013.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Nomura Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.